NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $14.83 -0.13 (-0.87%) Closing price 04:00 PM EasternExtended Trading$14.82 -0.01 (-0.03%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HUTCHMED Stock (NASDAQ:HCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HUTCHMED alerts:Sign Up Key Stats Today's Range$14.75▼$14.9550-Day Range$14.83▼$19.2152-Week Range$11.51▼$21.50Volume45,090 shsAverage Volume53,704 shsMarket Capitalization$2.59 billionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingBuy Company Overview HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. Read More HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreHCM MarketRank™: HUTCHMED scored higher than 53% of companies evaluated by MarketBeat, and ranked 524th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHUTCHMED has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHUTCHMED has only been the subject of 2 research reports in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth812.50% Earnings GrowthEarnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.23% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in HUTCHMED has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.23% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in HUTCHMED has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.33 News SentimentHUTCHMED has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for HUTCHMED this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for HCM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by InstitutionsOnly 8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesHUTCHMED (China) Limited: HUTCHMED Announces Appointment of Acting Chief Executive OfficerAugust 25 at 12:46 PM | finanznachrichten.deHUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEOAugust 25 at 7:45 AM | msn.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.August 28 at 2:00 AM | SmartAsset (Ad)HUTCHMED Announces Appointment of Acting Chief Executive OfficerAugust 24, 2025 | globenewswire.comHUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in ChinaAugust 19, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Rating Lowered by Wall Street ZenAugust 19, 2025 | americanbankingnews.comHUTCHMED (China) First Half 2025 Earnings: EPS: US$0.53 (vs US$0.03 in 1H 2024)August 9, 2025 | finance.yahoo.comHUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $14.41 at the beginning of 2025. Since then, HCM shares have increased by 2.9% and is now trading at $14.83. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHMED's major shareholders? Top institutional shareholders of HUTCHMED include Schroder Investment Management Group (1.48%), Allianz Asset Management GmbH (0.53%), M&G PLC (0.15%) and Jane Street Group LLC (0.10%). How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCM CIK1648257 Webwww.chi-med.com Phone852-2121-3888Fax852-2128-1778Employees1,811Year Founded2000Price Target and Rating Average Price Target for HUTCHMED$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+88.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio4.65 Quick Ratio4.51 Sales & Book Value Annual Sales$602.20 million Price / Sales4.30 Cash Flow$0.27 per share Price / Cash Flow54.42 Book Value$7.12 per share Price / Book2.08Miscellaneous Outstanding Shares174,422,000Free Float168,143,000Market Cap$2.59 billion OptionableNot Optionable Beta0.55 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:HCM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.